Drug intelligence / Profile preview

Melanight

Development stage: Unknown
Lead developer: Henning Arzneimittel
Modality: Small Molecules
Administration: Sublingual

Overview

Melanight is a melatonin-based sleep aid product developed and marketed by HENNIG ARZNEIMITTEL. It is formulated as an oral spray for sublingual administration, containing melatonin and Vitamin B6 (pyridoxine). Melatonin acts as an agonist at the MT1 and MT2 melatonin receptors, which are involved in the regulation of circadian rhythms and the promotion of sleep onset. The spray formulation is intended to provide superior bioavailability compared to traditional oral tablets. Melanight is indicated for reducing the time to fall asleep and alleviating the symptoms of jet lag. It was launched in Germany in 2021 as a dietary supplement and is suitable for vegans, being free from alcohol, lactose, and gluten.

Brand names: Melanight

Targets

MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on Melanight.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Melanight.

Explore the full profile